U.S. pharma huge copyright scrapped two experimental weight loss capsules last year—a as soon as-every day capsule, lotiglipron, because of elevated liver enzymes plus a two times-day by day tablet, danuglipron, due to robust Unintended effects—but CEO Albert Bourla has said the company is decided to “Perform and get” from the weight proble